Dr. Sylvia Adams on Tumor-Infiltrating Lymphocytes in Triple Negative Breast Cancer
Sylvia Adams, MD, medical oncologist, NYU Langone Medical Center, talks about the the importance of tumor-infiltrating lymphocytes (TILS) and how they can mark which patients will respond to immunotherapy use in triple negative breast cancer (TNBC). She discussed this topic at the recent Chemotherapy Foundation Symposium.
Sylvia Adams, MD, medical oncologist, NYU Langone Medical Center, talks about the the importance of tumor-infiltrating lymphocytes (TILS) and how they can mark which patients will respond to immunotherapy use in triple negative breast cancer (TNBC). She discussed this topic at the recent Chemotherapy Foundation Symposium.
She says that according to a study on 500 patients, these lymphocytes predict response to treatment in TNBC patients. She adds that the same results were seen in other investigators around the globe. This information is important to medical oncologists because it shows what types of breast cancers will potentially respond to immunotherapies.
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen
